Would you like to receive important updates about AbbVie Inc like earnings dates and more?
The Year To Date (YTD) return is +6.33%.
The 52 Week Low stock price is 59.27 set on Mon, Jan 30, 2017 which is 355 days ago.
The current price per share is 76.55% above the 52 week low.
The 52 Week High stock price is $104.87 set on Fri, Jan 19, 2018 which is 1 days ago.
The current price per share is -0.22% below the 52 week high.
The All Time High stock price is $104.87 set on Fri, Jan 19, 2018 which is 1 days ago.
The current price per share is -0.22% below the all time high.
The AbbVie 5 year stock chart shows the historical prices over the previous 60 months.
The AbbVie 1 year stock chart shows the historical prices over the previous 12 months.
The 50 Day Moving Average is at $72.13 which is 45.07% below the stock price of $104.64.
The 200 Day Moving Average is at 66.07 which is 58.38% below the stock price of $104.64.
Because both the 50 DMA and 200 DMA are below the current stock price, this can be considered a bullish technical indicator.
Since the stock price is very far from both moving averages, a price retracement towards the moving averages should not be unexpected.
AbbVie Inc is a Health Care stock that trades on the NYSE and has a market capitalization of $166.81 Billion.
ABBV is also one of the largest companies by market capitalization today.
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Below are several other Biotech & Pharma stocks include AbbVie Inc (ABBV), Allergan PLC (AGN), Alexion Pharmaceuticals Inc (ALXN), Amgen Inc (AMGN), Biogen Inc (BIIB), BioMarin Pharmaceutical Inc (BMRN), Bristol-Myers Squibb Co (BMY), Celgene Corp (CELG), Endo International PLC (ENDP), Gilead Sciences Inc (GILD), .
The EPS is $4.12.
The P/E Ratio is 25.42%.
The Earnings Release Date was Fri, Oct 27, 2017.
Since this earnings release 85 days ago, the stock price is up by +16.84%.
Many investors know the importance of a companies earnings report. Also, the market reaction to the earnings release can be even more important and can help in making a prediction of a future price forecast of the shares.
A significant post earnings announcement percentage move can continue or reverse an existing trend for several days or weeks after the earnings date.
The next Earnings Release Date is, before the market open, on Fri, Jan 26, 2018, which is in 6 days.
The Annual Dividend Yield is 2.71%.
AbbVie Inc is one of the few S&P 500 Dividend Aristocrats stocks.
The Dividend Aristocrats are S&P 500 constituents that have increased their dividend payouts for 25 consecutive years. The companies that make up the Dividend Aristocrats span ten different business sectors with both growth and value holdings. Wikipedia
Check out the Dividend Calculator to forecast your potential profis with AbbVie.
Since the Ex-Date on Thu, Jan 11, 2018, 9 days ago, the stock price is up by 5.41%. (The next ex-dividend date will be around Wed, Apr 11, 2018.)
The Pay Date is Thu, Feb 15, 2018 which is in 26 days.
Investors should understand the dividend history of a company. Dividend history will show the dividend payments disbursed to investors over the years.